Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;2(1):vdaa163. doi: 10.1093/noajnl/vdaa163

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — CD133^low/CD109^high group exhibits worse prognoses accompanied by an increase in mesenchymal signature. (A) Kaplan–Meier analysis of overall survival (left) and progression-free survival (right) of glioblastoma patients in CD133^low/CD109^low, CD133^high/CD109^low, CD133^high/CD109^high, and CD133^low/CD109^high (red, top to bottom) with each collected remaining cases (Others, blue). (Log-rank test). (B) River-plot analysis of the molecular subtype shifts from primary to recurrence in CD133^low/CD109^high (upper) and others (lower) (P = .028, chi-square test).